https://doi.org/10.1186/s13578-020-00403-5

provided by Qazvin University of Medical So

REVIEW

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

Open Access

PIWI-interacting RNAs: new biomarkers for diagnosis and treatment of breast cancer



AQ1

AQ5

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

Parisa Maleki Dana¹, Mohammad Ali Mansournia² and Seyyed Mehdi Mirhashemi^{3*}

Abstract

Cancer is one of the most important reasons of mortality in the world. However, there are several therapeutic platforms to treat patients who suffering from cancer common treatments such as surgery, chemotherapy and etc. The current therapeutic approaches are related to some limitations. Hence, more understanding about molecular mechanisms that involved in cancer particularly in breast cancer pathogenesis, could contribute to provide better therapeutic platforms. Recently, non-coding RNAs such as microRNAs have attracted researchers' attention in the field of cancer due to their functions in gene expression's regulation and functional interactions with other molecules. Interestingly, great advances in next-generation sequencing lead to considering other roles for another non-coding RNAs subgroup called PIWI-interacting RNAs (piRNAs) in addition to their functions in the germline. Novel studies investigated the role of piRNAs in several cancers including lung cancer, hepatocellular carcinoma, gastric cancer, multiple myeloma and colorectal cancer. Hopefully, based on new findings, piRNAs may be a potential biomarker which can be used as a tool to diagnose or treat breast cancer. Thus, this review aimed to discuss the role of piRNAs in breast cancer progression and metastasis as well as its molecular mechanisms.

Keywords: piRNA, Breast cancer, Epigenetic regulations

Background 19

20 Breast disorders are very important disorders among women [1]. Among them, Breast cancer is the most 21 common malignancy among women and it is the prin-22 ciple cause of women's death all over the world. In spite 23 of great progress in the field of cancer, breast cancer is 24 still a serious health problem among women which has 25 complicated properties heterogeneously and shows a 26 number of biological and clinical manifestations [2-4]. 27 Breast cancer has been categorized into five groups based 28 on expression patterns of three receptors: the estrogen 29 receptor, progesterone receptor and human epidermal 30 growth factor receptor. This categorization was a helpful 31 way in order to predict the outcome and choose the best 32

of Non-Communicable Diseases, Qazvin University of Medical Sciences, A3

A1

Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

treatment option [5, 6]. Mutations in BRCA1 and BRCA2

are some examples of genomic instabilities which are the

most prominent cause of breast cancer [7-9]. Several

studies indicated that a variety of techniques could be

used in the treatment of different cancers such as breast

cancer (i.e., cell-, gene-, and nanotechnology-based ther-

apies) [10–17]. Despite emerging new and effective ther-

apeutic platforms in the treatment of breast cancer, new

approaches are needed [18, 19]. In this regard, it seems

that more understanding of cellular and molecular path-

ways involved in breast cancer pathogenesis could con-

In the past, scientists called 98% non-protein coding

human genome as "junk" DNA. These DNAs produce

RNAs which are not translated into proteins. This group

is known as non-coding RNAs (non-encoding RNAs)

which has two main subgroups: regulatory non-coding

RNAs and housekeeping non-coding RNAs. The regula-

tory non-coding RNAs are also sorted into two subdivi-

sions by their length: short chain non-coding RNAs and

tribute to the development of new therapies [18].



Journal : BMCTwo 13578	Dispatch : 13-3-2020	Pages : 8	_
Article No: 403	□ LE	□ TYPESET	
MS Code :	☑ CP	🗹 DISK	

^{*}Correspondence: mirhashemismm@gmail.com; sm.mirhashemi@gums.ac.ir

³ Metabolic Diseases Research Center, Research Institute for Prevention A2

Qazvin, Iran A4 A5